A Safer Path to “Ozempic”: Vitable Health Challenges the “Prescription-First” Trend with a GLP-1 Program Built on Primary Care
PHILADELPHIA–(BUSINESS WIRE)–Vitable Health, the leading all-in-one health benefits platform redefining care for the American workforce, announced the launch of its GLP-1-based weight management services and comprehensive preventative lab panels, now available through its fully integrated Direct Primary Care (DPC) services. As the GLP-1 boom continues, many platforms and compounding pharmacies are rushing to capitalize on […]
Novo Nordisk launches Wegovy in India to rival Eli Lilly’s weight-loss drug
Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly’s Mounjaro
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here’s What Investors Need to Know
On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on the news. It wasn’t a marriage made in heaven. Novo Nordisk revealed on Monday that it will no longer work […]
Rival GLP-1 Weight-Loss Drug Emerges From China – U.S. News & World Report
Rival GLP-1 Weight-Loss Drug Emerges From China U.S. News & World Report
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Post Content
Rival GLP-1 Weight-Loss Drug Emerges From China
By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new…
Semaglutide Users Are Reporting ‘Ozempic Teeth’ – But It May Not Be What They Think
Teeth You may have already heard of “Ozempic penis,” an often-welcome illusion that some on weight loss jabs experience which makes their genitals look bigger. Though the medication cannot actually increase the size of your bits, it can improve your blood flow and reduce the amount of fat in the suprapubic area – removing what urologist Dr […]
Dual-Target Weight Loss Treatment Shows Promise
Amycretin — a novel obesity treatment that targets both GLP-1 and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. Medscape Medical News
Blockbuster weight loss jabs ‘significantly lower’ the risk of dementia
WEIGHT loss jabs may also help ward off dementia, a new study suggests. Researchers found that semaglutide – the active ingredient in Ozempic and Wegovy – could “significantly” slash the risk of the brain-robbing disease in people with type 2 diabetes. GettyWeight loss and antidiabetic jabs like Ozempic and Wegovy could have other health benefits[/caption] […]
Rival GLP-1 Weight-Loss Drug Emerges From China – Wyoming News Now
Rival GLP-1 Weight-Loss Drug Emerges From China Wyoming News Now